Follitropin alpha linked to increased pregnancy and live births in real world setting

In comparison to biosimilars, Gonal-f®(originator follitropin) medication may lead to greater pregnancy rates and live birth rate (LBR), says an article published in the Journal of Human Reproductive Science.

The therapeutic choices for assisted reproductive technology (ART) have expanded thanks to biosimilar medications. To improve the body of evidence for clinical decision-making on drug choice, real-world data comparing the clinical outcomes of the original follitropin alfa (Gonal-f®) with its biosimilars are needed. In order to assess the results of ART in patients receiving the original follitropin (Gonal-f®) and its biosimilars in a clinical context, Nayana Hitesh Patel and colleagues undertook this study.

Retrospective analysis was done on the medical records of 364 infertile women who received ART at Akanksha Hospital and Research Institute in Gujrat, India, between 2016 and 2020. Each cohort was then separated into group A (age 35 years) and group B (age 35 years) depending on the therapy given to the participants (Gonal-f® cohort, N = 174, and biosimilar cohort, N = 190). Transfer of fresh or frozen embryos was done in accordance with the clinic's established protocols. The key main outcome indicators in this study were the prevalence of pregnancy and the live birth rate. Analyses were conducted using descriptive statistics and the Chi-square test.